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Abstract. Lung cancer is the leading cause of cancer-associated 
mortality worldwide, and the mainstay of treatment remains 
to be personalised therapy. Tyrosine kinase inhibitors of the 
epidermal growth factor receptor (EGFR-TKIs) have been 
reported to exert a significant impact in the treatment of 
non-small cell lung cancer (NSCLC), particularly in patients 
harbouring mutations in the EGFR gene. The echinoderm 
microtubule-associated protein-like 4-anaplastic lymphoma 
kinase (EML4‑ALK) gene translocation has been described 
in a subset of patients with NSCLC and possesses potent 
oncogenic activity. This translocation represents one of the 
most novel molecular targets in the treatment of NSCLC. 
Patients who harbour the EML4‑ALK rearrangement 
possess lung tumours that lack EGFR or K‑ras mutations. 
The present study reports the case of a patient possessing 
the EML4‑ALK rearrangement that was initially treated with 
erlotinib and achieved a lasting clinical response. To the 
best of our knowledge, the current study is the first report 
of a clinical response to EGFR-TKI in a patient with lung 
adenocarcinoma harbouring the EML4‑ALK fusion gene, but 
no EGFR mutations. However, as the disease progressed, the 
ALK gene status of the tumour was investigated, and based 
upon a positive result, the patient was treated with crizotinib 
and achieved a complete response. In conclusion, the present 
study suggests that the EML4‑ALK rearrangement is not 
always associated with resistance to EGFR-TKIs. Further 
studies are required to clarify the biological features of these 
tumours and to investigate the mechanisms underlying the 
primary resistance to EGFR-TKIs when the EML4‑ALK 
rearrangement is present.
Introduction
Despite improvements in the detection and treatment of lung 
cancer, it remains the most common cause of cancer-associated 
mortality worldwide (1). Although the mainstay of treatment 
for the majority of patients with advanced non-small cell lung 
cancer (NSCLC) continues to be cytotoxic chemotherapy (2), 
novel targeted therapies in NSCLC patients have been devel-
oped due to the identification of specific genetic lesions that 
drive the proliferation of cancer cells (3,4).
Tyrosine kinase inhibitors of the epidermal growth factor 
receptor (EGFR‑TKIs), including gefitinib and erlotinib, have 
been revealed to significantly impact the treatment of patients 
with NSCLC. Patients harbouring mutations in the EGFR 
gene, in particular, experience a greater clinical benefit from 
EGFR-TKIs compared with traditional cytotoxic chemo-
therapy administered as first‑line, second‑line or maintenance 
therapy (5,6).
In previous studies, the echinoderm microtubule-associated 
protein-like 4-anaplastic lymphoma kinase (EML4‑ALK) 
gene translocation has been identified in a subset of patients 
with NSCLC, characterized by distinct clinicopathological 
features, including a lower age at onset (median ago of 
52 years compared with 66 years in patients with the EGFR 
mutation), adenocarcinoma histology and a history of never 
or light smoking (4-8). This fusion gene, which causes the 
constitutive expression of ALK, induces oncogenic cell 
transformation in vitro and in vivo (9). In NSCLC, the ALK 
rearrangement has been reported to be associated with distinct 
clinicopathological characteristics, including a lower age at 
onset, adenocarcinoma histology and a history of never or light 
smoking (8). In the majority of cases, this rearrangement and 
other well-known oncogenic mutations, including the EGFR 
and K‑ras mutations, are mutually exclusive (8). Crizotinib, a 
Response to erlotinib in a patient with lung adenocarcinoma 
harbouring the EML4-ALK translocation: A case report
GRETA ALÌ1,  ANTONIO CHELLA2,  CRISTIANA LUPI1,  AGNESE PROIETTI3,  CRISTINA NICCOLI3,  
LAURA BOLDRINI3,  FEDERICO DAVINI4,  ALFREDO MUSSI5  and  GABRIELLA FONTANINI3
Departments of 1Pathological Anatomy and 2Pneumology, Azienda Ospedaliera Universitaria Pisana;  
3Department of Surgical, Medical, Molecular Pathology and Critical Care, Division of Pathological Anatomy, 
University of Pisa; 4Unit of Thoracic Surgery, Azienda Ospedaliera Universitaria Pisana;  
5Department of Surgical, Medical, Molecular Pathology and Critical Care, 
Division of Thoracic Surgery, University of Pisa, Pisa, Tuscany I-56126, Italy
Received February 10, 2014;  Accepted November 25, 2014
DOI: 10.3892/ol.2015.2897
Correspondence to: Dr Gabriella Fontanini, Department of 
Surgery, Medical, Molecular, Pathology and Critical Care, Division 
of Pathological Anatomy, University of Pisa, 57 Via Roma, Pisa, 
Tuscany I-56126, Italy
E-mail: gabriella.fontanini@med.unipi.it
Key words: EML4‑ALK rearrangement, lung adenocarcinoma, 
erlotinib, crizotinib
ALÌ et al:  TARGETED THERAPY FOR LUNG ADENOCARCINOMA1538
small-molecule dual inhibitor of c-MET and the ALK receptor 
tyrosine kinase, has previously demonstrated a significant 
clinical benefit in patients with EML4‑ALK-positive NSCLC 
in a clinical trial (10,11). Written informed consent was 
obtained from the patient.
Case report
The present study reports the case of a never-smoking 
61-year-old female that presented to the Azienda Ospedaliera 
Universitaria Pisana (Pisa, Italy) in June 2006 due to a persis-
tent cough. A thoracic computed tomography (CT) revealed 
the presence of an irregular nodule, ~2.5 cm in diameter, in 
the lower lobe of the right lung. Fluorodeoxyglucose positron 
emission tomography (FDG-PET) examination revealed 
the presence of anomalous tracer uptake in the lung nodule, 
without pathological adenopathy. The patient underwent a right 
lobectomy and right superior pulmonary hilar and mediastinal 
lymphadenectomy. The histological diagnosis was invasive 
lung adenocarcinoma, with a mucinous growth pattern, areas 
of papillary pattern and signet ring cell features, and visceral 
pleura infiltration (Fig. 1). Metastases of the adenocarcinoma 
were observed in two carinal lymph nodes, resulting in a path-
ological tumour-node-metastasis (pTNM) staging of pT2aN2. 
Therefore, the patient underwent adjuvant radiotherapy (60 Gy) 
and four cycles of chemotherapy with carboplatin (6 AUC)and 
paclitaxel (250 mg/m2) for three months. The mutational status 
of the EGFR gene was analysed using single-strand conforma-
tional polymorphism (SSCP) and direct sequencing, and was 
found to be negative for mutations in exons 18, 19, 20 and 21 of 
the gene. 
In January 2010, the patient exhibited disease progres-
sion (PD), with the appearance of small nodules (maximum 
diameter, 15.0 mm) in the upper and lower lobes of the left 
lung (Fig. 2A). Due to the refusal of the patient to undergo 
additional chemotherapy, treatment consisting of 150 mg erlo-
tinib once a day commenced, which led to stable disease (SD) 
until May 2011. At that time, stereotactic radiotherapy was 
performed on a nodule of the lower left lobe that demonstrated 
a small increase in size between 15.0 and 17.5 mm (Fig. 2B). 
However, the patient continued treatment with erlotinib, 
and SD continued until June 2012 when all the lesions of 
the left lung demonstrated progression, with increases in 
size (Fig. 2C). After 28 months of treatment with erlotinib, 
chemotherapy with cisplatin and pemetrexed was then started. 
Following four cycles, a partial response (PR) was observed 
on a CT scan (Fig. 2D), but subsequent to six cycles, the 
lesions exhibited minimal progression. A second surgery 
was performed, and the patient underwent resection of three 
nodules in the left upper lobe and two nodules in the left lower 
lobe in December 2012. A histological diagnosis of pulmonary 
adenocarcinoma was made for all resected lesions. 
The mutational status of the EGFR and K‑ras genes and 
the translocation status of the EML4‑ALK fusion gene were 
analysed in one of the lesions of the left lower lobe. EGFR 
mutational analysis was performed using SSCP and direct 
sequencing, whereas pyrosequencing assays were performed 
for the sequence analysis of K‑ras. The tumour did not harbour 
either the EGFR or K-ras mutation. Fluorescence in situ hybrid-
ization (FISH), which was performed using a break-apart probe 
for ALK (Abbott Molecular, Des Plaines, IL, USA), detected 
the presence of the EML4‑ALK rearrangement. According 
to the scoring method proposed by Kwak et al (10), the test 
result for this specimen was considered positive as 38% of the 
neoplastic cells were positive for the EML4‑ALK rearrange-
ment (Fig. 3A). In addition, immunohistochemical staining of 
the lesion tissue using a rabbit monoclonal primary anti-ALK 
antibody (clone D5F3; Ventana Medical Systems, Inc., Tucson, 
AZ, USA) in combination with an OptiView 3,3'-diaminoben-
zidine Immunohistochemistry Detection kit and an OptiView 
Amplification kit (Ventana) revealed strong granular 
cytoplasmic expression of the ALK protein (Fig. 3B). Immu-
nostaining was performed by a fully automated assay using 
a BenchMark XT automated slide stainer (Ventana Medical 
Systems, Inc.). Molecular analysis for K‑ras mutation and the 
EML4‑ALK fusion gene were also performed on the tumour 
resection specimen from 2006. The absence of mutation in 
the K‑ras gene and the presence of the EML4‑ALK rearrange-
ment were confirmed by FISH and immunohistochemistry. In 
August 2013, a CT of the chest revealed PD with novel left 
lung lesions (Fig. 4A). Treatment with oral crizotinib (250 mg 
twice daily) was then started. A repeat chest CT (Fig. 4B) three 
months later demonstrated dramatic shrinkage of the lesions. 
The patient is continuing the treatment with crizotinib and at 
the date of the last follow-up (October, 2014), the patient was 
well and any disease recurrence was identified.
Discussion
Treatment for lung cancer has tended towards personalised 
therapy. Gefitinib and erlotinib, small molecules that inhibit 
the tyrosine kinase activity of EGFR, are a recognized treat-
ment for patients with advanced NSCLC. In particular, the 
presence of EGFR mutations is strongly associated with 
patient response to these drugs (5,6). The EML4‑ALK fusion 
oncogene has previously been identified in a subset of patients 
with NSCLC (4-7) and represents one of the most novel 
molecular targets for the treatment of NSCLC. Crizotinib 
has resulted in an excellent clinical response in patients 
with EML4‑ALK-positive NSCLC (10,11). Certain clinico-
pathological characteristics of EML4‑ALK-positive NSCLCs, 
including a young age at onset, lack of a smoking history and 
adenocarcinoma histology (8), are also observed in patients 
with NSCLC that harbours EGFR mutations (3). However, 
the ALK rearrangement is thought to be mutually exclusive to 
other mutations in NSCLCs (7), with rare exceptions (12). In 
Figure 1. Lung adenocarcinoma exhibiting a mucinous growth pattern, areas 
of papillary pattern and signet ring cell features (magnification, x10).
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addition, the ALK translocation is considered to be a potential 
mechanism of resistance to the efficacy of EGFR‑TKIs (9,12). 
In a preclinical study, patients with EML4‑ALK-positive 
NSCLC were found to not respond to erlotinib therapy (12). 
Shaw et al (8) described the clinical response to EGFR-TKIs 
of 10 patients with the EML4‑ALK rearrangement and found 
that none of them responded to erlotinib.
A clinical response to EGFR-TKIs in patients with 
EML4‑ALK-positive lung adenocarcinoma has been previously 
observed in cases that harbour a coexisting EGFR mutation 
and EML4‑ALK translocation (13-15). However, discordant 
results have been reported by studies investigating tumours 
with these concomitant molecular alterations, resulting in 
resistance and response to the same drug being reported by 
different studies (13-17).
The present study described the case of a patient with the 
EML4‑ALK rearrangement that was initially treated with 
erlotinib and experienced a lasting clinical response. Although 
the ALK inhibitor is an effective drug for the treatment of 
EML4‑ALK-positive NSCLC (10,11), the current patient was 
not initially evaluated for the presence of the translocation, as 
the indication was not included in clinical practice guidelines 
at the time of relapse (January 2010). In the absence of genetic 
testing for the EML4‑ALK fusion gene, EML4‑ALK-positive 
Figure 4. Comparison of (A) the initial computed tomography (CT) of the thorax and (B) the repeat CT three months after initiation of crizotinib therapy, 
demonstrating the dramatic shrinkage of the tumour lesions.
Figure 3. (A) Fluorescence in situ hybridisation analysis of the lung tumour specimen revealing cells with characteristic ALK translocation identified by one normal 
(paired) signal and two pairs of separated signals (arrows) (magnification, x100). (B) Immunohistochemical staining for the ALK protein revealing strong granular 
cytoplasmic expression in the lung adenocarcinoma specimen (magnification, x10). ALK, anaplastic lymphoma kinase.
Figure 2. (A) Thoracic computed tomography (CT) revealing a sub-centimetre lesion, 8.0 mm in diameter, in the lower lobe of the left lung that (B) demon-
strated a small increase in size after 17 months. (C) CT scan revealed progression with an increase in the size of the lesions of the left lung and (D) demonstrated 
a partial response following four cycles of chemotherapy with cisplatin and pemetrexed.
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patients are likely to be treated in the same manner as patients 
with EGFR mutations. The present patient was treated with 
EGFR-TKI due to clinicopathological characteristics that 
included female gender, young age, history of non-smoking 
and the refusal to undergo additional chemotherapy. To the 
best of our knowledge, the present study is the first reported 
case with a clinical response to EGFR-TKIs in a patient with 
lung adenocarcinoma harbouring the EML4‑ALK fusion gene 
and in the absence of EGFR mutations. At the time of the 
second surgery, molecular analysis was performed to investi-
gate whether the tumour possessed the ALK fusion gene. The 
analysis was conducted on the primary and relapse tumour 
specimens. Notably, the EML4‑ALK rearrangement was 
detected in the two specimens, but no EGFR mutations were 
identified. From the time of disease progression, the patient 
was treated with crizotinib and achieved a complete response, 
confirming that patients with this chromosomal translocation 
can benefit from specific ALK inhibition.
In conclusion, the present results suggest that the 
EML4‑ALK rearrangement is not always associated with 
resistance to EGFR-TKI therapy. Future studies are required 
to clarify the biological features of these tumours and inves-
tigate the mechanisms underlying the primary resistance to 
EGFR-TKIs when the EML4‑ALK rearrangement is present. 
Furthermore, the present case highlights the importance of 
screening patients with NSCLC by molecular testing to iden-
tify the best therapeutic approach for these patients.
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